Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Human-Papillomavirus-Related Squamous Cell Carcinoma: From Pathogenesis to Treatment
share announcement

Advances in Human-Papillomavirus-Related Squamous Cell Carcinoma: From Pathogenesis to Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 20 January 2025 | Viewed by 4783

Special Issue Editors

Dr. Silvana Canevari

E-Mail Website
Guest Editor
Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
Interests: cancer biology; cancer genomics; head and neck cancer; gynecological cancers
Dr. Loris De Cecco

E-Mail Website
Guest Editor
Molecular Mechanisms Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
Interests: cancer biology; cancer genomics; head and neck cancer; ovary cancer; pediatric tumors
Dr. Stefano Cavalieri

E-Mail Website
Guest Editor
1. Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133 Milan, Italy
2. Department of Oncology and Hemato-Oncology, University of Milan, Via Santa Sofia 9/1, 20122 Milan, Italy
Interests: head and neck cancer; medical oncology; clinical diagnosis; clinical treatment

Special Issue Information

Dear Colleagues,

We are pleased to invite you to this Special Issue. Based on the present knowledge, approximately 5% of the world's cancers are specifically attributed to HPV. While the greatest global burden of HPV is cervical cancers in low- and middle-income countries, HPV-associated head and neck cancers are increasing in high-income countries and have surpassed cervical cancer as the primary HPV-associated cancer in some countries. Open questions include the not well-understood mechanisms responsible for the persistence of infection, the unclear prognostic significance of HPV status in patients with head and neck squamous cell carcinomas outside of the oropharynx, the de-escalation treatments for patients with HPV+ oropharyngeal cancer, and the relationship between HPV and radiotherapy sensitivity in cervical cancer.

This Special Issue aims to contribute to an improved understanding of the molecular basis and of the clinical course of HPV-positive cancer to guide efforts towards early detection and precision care and to improve patient outcomes. In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

Dr. Silvana Canevari
Dr. Loris De Cecco
Dr. Stefano Cavalieri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • HPV
  • head and neck cancer
  • oropharynx
  • cervical cancer
  • genomics
  • metabolomics
  • tumor heterogeneity
  • microenvironment
  • biomarkers
  • epidemiology and vaccine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 1218 KiB  
Communication
Concomitant Cervical and Anal Screening for Human Papilloma Virus (HPV): Worth the Effort or a Waste of Time?
by Camille Chilou, Iolanda Espirito Santo, Seraina Faes, Pénélope St-Amour, Martine Jacot-Guillarmod, Basile Pache, Martin Hübner, Dieter Hahnloser and Fabian Grass
Cancers 2024, 16(20), 3534; https://doi.org/10.3390/cancers16203534 - 19 Oct 2024
Viewed by 515
Abstract
Background: This study represents a follow-up analysis of the AnusGynecology (ANGY) study. Methods: This prospective, cross-sectional, single-center study recruited women for concomitant cervical and anal screening of HPV genotypes and cytology during a single appointment. All women with findings of either HPV or [...] Read more.
Background: This study represents a follow-up analysis of the AnusGynecology (ANGY) study. Methods: This prospective, cross-sectional, single-center study recruited women for concomitant cervical and anal screening of HPV genotypes and cytology during a single appointment. All women with findings of either HPV or any type of dysplastic lesions on anal smears were offered follow-up in a specialized high-resolution anoscopy (HRA) outpatient clinic, representing the study cohort for this follow-up study. Results: Overall, 275 patients (mean age 42 ± 12) were included. Among them, 102 (37%) had cervical high-risk (HR) HPV. In total, HPV was (incidentally) revealed in 91 patients (33%) on anal smears, while any degree of anal squamous intraepithelial lesion (SIL) was found in 30 patients (11%), 6 if which were high-grade SIL (H-SIL). Furthermore, 10 out of 19 biopsies were positive (3 H-SIL lesions). Only half (48/91, 53%) of the women agreed to undergo the recommended specialized follow-up evaluation. Of them, 18 (38%) were diagnosed with dysplastic lesions (9 low grade (L-SIL) and 9 H-SIL, respectively) on biopsies, while the remaining visits revealed no abnormalities. Multivariable analysis revealed cervical HR-HPV infection (OR 4, 95% CI 2.2–7.5) and anal intercourse (OR 3.1, 95% CI 1.7–5.9) as independent risk factors for anal HR-HPV infection. Conclusions: Close follow-up of these women is hence strongly recommended. Full article
(This article belongs to the Special Issue Advances in Human-Papillomavirus-Related Squamous Cell Carcinoma: From Pathogenesis to Treatment)
►▼ Show Figures

Figure 1

9 pages, 342 KiB  
Article
Accuracy of GynTect® Methylation Markers to Detect Recurrent Disease in Patients Treated for CIN3: A Proof-of-Concept Case-Control Study
by Heike Hoyer, Cornelia Scheungraber, Grit Mehlhorn, Ingke Hagemann, Sarah Scherbring, Linn Wölber, Annett Petzold, Kristina Wunsch, Martina Schmitz, Monika Hampl, Gerd Böhmer, Peter Hillemanns, Ingo B. Runnebaum and Matthias Dürst
Cancers 2024, 16(17), 3022; https://doi.org/10.3390/cancers16173022 - 30 Aug 2024
Viewed by 546
Abstract
Post-treatment follow-up in women with CIN3 is mandatory due to relapse in up to 15% of patients within 2 years. Standard follow-up care based on hrHPV-DNA/cytology co-testing has high sensitivity but limited specificity. The aim of our proof-of-concept case-control study was to evaluate [...] Read more.
Post-treatment follow-up in women with CIN3 is mandatory due to relapse in up to 15% of patients within 2 years. Standard follow-up care based on hrHPV-DNA/cytology co-testing has high sensitivity but limited specificity. The aim of our proof-of-concept case-control study was to evaluate the performance of the methylation test GynTect® for the detection of recurrent CIN2/3 during follow-up. Residual clinical material from a recent, prospective, multicenter, observational study was available for further analysis. We studied a sample of 17 cases with recurrent CIN2/3 diagnosed within 24 months of follow-up and 31 controls without recurrence. DNA from cervical scrapes at baseline (immediately before CIN3 surgery) and up to three follow-up visits were analyzed for hrHPV and GynTect® methylation status. Cytology data were available from the previous study. Overall, 12 cases and 21 controls were GynTect-positive at baseline. In these subgroups, single test sensitivity at first follow-up was 67% (95% CI 39–87%) for GynTect® compared to 83% (95% CI 55–96%) for hrHPV (p = 0.50). Single test specificity was significantly higher for GynTect® (90%, 95% CI 71–98% vs. 62%, 95% CI 40–80%) (p = 0.03). In a co-testing setting, both hrHPV/cytology and GynTect®/cytology detected all recurrences. Specificity for GynTect®/cytology was higher than for hrHPV/cytology, but this difference was not statistically significant. In conclusion, for initially GynTect-positive patients, both hrHPV and GynTect® tests detected recurrent disease with similar sensitivity, but the GynTect® assay has a higher specificity. Incident hrHPV infection and/or persisting multifocal hrHPV infections without clinical disease are most likely responsible for the poorer specificity of the hrHPV test. A future prospective validation study will have to show whether GynTect®/cytology co-testing can outperform hrHPV/cytology co-testing in post-treatment surveillance. Full article
(This article belongs to the Special Issue Advances in Human-Papillomavirus-Related Squamous Cell Carcinoma: From Pathogenesis to Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 990 KiB  
Review
A Comprehensive Review of Genistein’s Effects in Preclinical Models of Cervical Cancer
by Matteo Nadile, Amanda Kornel, Newman Siu Kwan Sze and Evangelia Tsiani
Cancers 2024, 16(1), 35; https://doi.org/10.3390/cancers16010035 - 20 Dec 2023
Cited by 2 | Viewed by 1406
Abstract
Cervical cancer is associated with persistent Human Papilloma Virus (HPV) infections and is the fourth most common cancer in women worldwide. Current treatment options; surgery, chemotherapy, and radiation, are often associated with severe side effects including possible infertility. Novel treatment options are required [...] Read more.
Cervical cancer is associated with persistent Human Papilloma Virus (HPV) infections and is the fourth most common cancer in women worldwide. Current treatment options; surgery, chemotherapy, and radiation, are often associated with severe side effects including possible infertility. Novel treatment options are required to help combat this disease and reduce side effects. Many plant-derived chemicals, including paclitaxel and docetaxel, are already in use as treatments for various cancers. Genistein is a polyphenolic isoflavone found in foods including soybeans and legumes, and studies have shown that it has various biological effects and anti-cancer properties. This review aims to summarize the existing studies examining the effects of genistein on cervical cancer. All relevant in vitro and in vivo studies are summarized, and the key findings are highlighted in the associated tables. Based on the available in vitro/cell culture studies reported here, genistein inhibits cervical cancer cell proliferation and induces apoptosis. Use of genistein in combination with radiation or chemotherapy agents resulted in enhanced response indicating radio- and chemo-sensitization properties. More animal studies are required to examine the effectiveness of genistein in vivo. Such studies will form the basis for future human studies exploring the potential of genistein to be used in the treatment of cervical cancer. Full article
(This article belongs to the Special Issue Advances in Human-Papillomavirus-Related Squamous Cell Carcinoma: From Pathogenesis to Treatment)
►▼ Show Figures

Figure 1

31 pages, 2018 KiB  
Review
Epigenetic and Genetic Keys to Fight HPV-Related Cancers
by Veronica Folliero, Federica Dell’Annunziata, Annalisa Chianese, Maria Vittoria Morone, Francesca Mensitieri, Federica Di Spirito, Antonio Mollo, Massimo Amato, Massimiliano Galdiero, Fabrizio Dal Piaz, Pasquale Pagliano, Luca Rinaldi and Gianluigi Franci
Cancers 2023, 15(23), 5583; https://doi.org/10.3390/cancers15235583 - 25 Nov 2023
Cited by 5 | Viewed by 1733
Abstract
Cervical cancer ranks as the fourth most prevalent cancer among women globally, with approximately 600,000 new cases being diagnosed each year. The principal driver of cervical cancer is the human papillomavirus (HPV), where viral oncoproteins E6 and E7 undertake the role of driving [...] Read more.
Cervical cancer ranks as the fourth most prevalent cancer among women globally, with approximately 600,000 new cases being diagnosed each year. The principal driver of cervical cancer is the human papillomavirus (HPV), where viral oncoproteins E6 and E7 undertake the role of driving its carcinogenic potential. Despite extensive investigative efforts, numerous facets concerning HPV infection, replication, and pathogenesis remain shrouded in uncertainty. The virus operates through a variety of epigenetic mechanisms, and the epigenetic signature of HPV-related tumors is a major bottleneck in our understanding of the disease. Recent investigations have unveiled the capacity of viral oncoproteins to influence epigenetic changes within HPV-related tumors, and conversely, these tumors exert an influence on the surrounding epigenetic landscape. Given the escalating occurrence of HPV-triggered tumors and the deficiency of efficacious treatments, substantial challenges emerge. A promising avenue to address this challenge lies in epigenetic modulators. This review aggregates and dissects potential epigenetic modulators capable of combatting HPV-associated infections and diseases. By delving into these modulators, novel avenues for therapeutic interventions against HPV-linked cancers have come to the fore. Full article
(This article belongs to the Special Issue Advances in Human-Papillomavirus-Related Squamous Cell Carcinoma: From Pathogenesis to Treatment)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop